It’s being called a “sharpened tool.”

Pfizer announced in a 22 August press release that they have applied for Emergency Use Authorization (EUA) approval of a “bivalent” COVID vaccine.

Sound familiar?

According to the press release:

“The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein, which is present in the original Pfizer-BioNTech COVID-19 Vaccine, together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5-adapted bivalent vaccine in individuals 12 years of age and older is expected to start this month.”

The statement said that the submission to the U.S. Food and Drug Administration (FDA) regards a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

A July 2022 Nature magazine article detailed the difficulties of trying to produce effective vaccines for the COVID virus, characterizing the process as “shifting sands.”

The article noted that some scientists believe it is likely that entirely new variants will emerge that are far removed from similarity to current  SARS-CoV-2 strains, making vaccines potentially of little use.

“My concern is that there’s this huge focus on Omicron, and the assumption that Omicron is what we will be dealing with in the future,” virologist Penny Moore of the University of the Witwatersrand in Johannesburg, South Africa, was quoted in the article. “We have a strong track record of getting that wrong.” 

Reports of Injuries From Previous mRNA and DNA COVID Experimental Therapies Growing

Big Pharmaceuticals have profiteered from plying governments to push their vaccines, despite mounting evidence that their experimental and controversial technologies are harming people at greater rates than previously acceptable for traditional vaccines.

The Trends Journal has covered issues surrounding COVID gene level technologies and pharmaceutical company outsized profits in many articles. Samples include: 

Skip to content